Clinical Trial

NX-5948-201: A Single-arm, Phase 2, Open-label, Multicenter Study to Evaluate NX-5948 in Adults with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Previously Exposed to a Bruton’s Tyrosine Kinase Inhibitor (BTKi) and a B-cell Lymphoma-2 Inhibitor (BCL-2i)

MOA: NX-5948 (bexobrutideg) is a CTM that induces the degradation of BTK in cells through recruitment of CRBN and promotes the formation of a ternary complex of CRBN, NX-5948, and BTK.

Key Eligibility Criteria:

• Confirmed diagnosis of relapsed/refractory CLL/SLL
• ECOG ≤2
• Subjects must have prior exposure to a cBTKi, ncBTKi, and BCL-2i either in separate LOT or in combination
• Subjects must have measurable disease by CT
• Subjects previously treated with a BTK degrader are excluded
• Subjects with a known or suspected prolymphocytic
  leukemia or Richter’s transformation are excluded